Pulmonary drug delivery for acute respiratory distress syndrome
Pulmonary Pharmacology & Therapeutics · 2023
DOI: 10.1016/j.pupt.2023.102196 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2023. Verfasst von Qinqin Fei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH, 43210, USA; Division …. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, Pulmonary Surfactants. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Eli Lilly and Company, National Institutes of Health.
Abstract (Originalsprache)
The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery during ARDS offers several potential advantages including limiting the off-target and off-organ effects and directly targeting the damaged and inflamed lung regions. In this review we summarize recent ARDS clinical trials using both systemic and pulmonary drug delivery. We then discuss the advantages of pulmonary drug delivery and potential challenges to its implementation. Finally, we discuss the use of nanoparticle drug delivery and surfactant-based drug carriers as potential strategies for delivering therapeutics to the injured lung in ARDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH, 43210, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Interna…
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Columbus, OH, 43210, USA; The Davis Heart and Lung Resear…
- Department of Biomedical Engineering, The Ohio State University, 140West 19th Avenue, Columbus, OH, 43210, USA; The Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, 473 West 12th…
Förderung
- NHLBI NIH HHS
- Eli Lilly and Company
- National Institutes of Health
Zitieren
APA
Fei, Q., Bentley, I., Ghadiali, S. N., & Englert, J. A. (2023). Pulmonary drug delivery for acute respiratory distress syndrome. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2023.102196
Vancouver
Fei Q, Bentley I, Ghadiali SN, Englert JA. Pulmonary drug delivery for acute respiratory distress syndrome. Pulmonary Pharmacology & Therapeutics. 2023. doi:10.1016/j.pupt.2023.102196
BibTeX
@article{Fei2023,
author = {Fei, Qinqin and Bentley, Ian and Ghadiali, Samir N and Englert, Joshua A},
title = {Pulmonary drug delivery for acute respiratory distress syndrome},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1016/j.pupt.2023.102196}
}
EUVIMED